It was a pleasure to talk with Daniel Chappell (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) around the feasibility study investigating rates of osteoporosis in people undergoing routine diagnostic CT scans and the potential of routine osteoporosis screening in future clinical practice.
The abstract ‘Osteoporosis case-finding in people undergoing routine diagnostic CT scans almost tripled the rate of osteoporosis treatment at 12 months. A randomised, multi-centre feasibility study using waiting room FRAX, opportunistic CT bone density and vertebral fracture assessment versus usual care.‘ (Abstract number: OP0243) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
- How often is osteoporosis found in CT scans taken for other reasons? (0:11)
- What were the objectives, design and eligibility criteria of your study? (0:41)
- What were the primary and secondary outcome measures, and what were the results? (1:24)
- What would be the potential clinical impact of embedding osteoporosis screening into CT-based diagnostic scans? (3:37)
- What questions remain unanswered and what future studies are planned? (5:13)
Disclosures: Daniel Chappell has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
Share this Video
Related Videos In Rheumatic Diseases
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Catherine Sims, ACR 2022: Azathioprine metabolite levels throughout pregnancy in women with rheumatic disease
Women with rheumatic disease, such as systemic lupus erythematosus, are often prescribed azathioprine to control disease activity during pregnancy. However, the changes in azathioprine metabolite levels throughout pregnancy in such women are yet to be well-characterized. It was a pleasure to talk with Dr. Catherine Sims (Duke University, Durham, NC, USA) around her study investigating […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!